Olanap 5: Each tablet contains Olanzapine USP 5 mg.
Olanap 5 ODT: Each orodispersible tablet contains Olanzapine USP 5 mg.
Olanap 10: Each tablet contains Olanzapine USP 10 mg.
Olanap 10 ODT: Each orodispersible tablet contains Olanzapine USP 10 mg
Olanzapine is a selective monoaminergic antagonist with high affinity binding to serotonin 5-HT, dopamine, muscarinic, H1 and alpha receptors. It has weak binding affinity to GABA-A,
benzodiazepine and beta adrenergic receptors
• Prevention of Bipolar Disorder
Schizophrenia, combination therapy for Mania, Bipolar Disorder:
The initial dose is 5-10 mg once daily. Daily dosage may subsequently be adjusted on the basis of individual clinical status within the range of 5-20 mg daily. Dosage greater than 10 mg daily only after reassessment. Maximum dose is 20 mg daily.
Monotherapy for Mania:
Initially 15 mg once daily. Daily dosage may subsequently be adjusted on the basis of individual clinical status within the range of 5-20 mg daily. Dosage greater than 15 mg only after reassessment. Maximum dose is 20 mg daily.
Olanzapine can be given without regard to meals. Gradual tapering of the dose should be considered while discontinuing Olanzapine.
Very common undesirable effects are somnolence and weight gain. Besides increased appetite, elevated glucose levels, elevated triglyceride levels, dizziness, akathisia, Parkinson's disease, dyskinesia, orthostatic hypotension, mild and transient anticholinergic effects including constipation and dry mouth, asthenia, edema and photosensitivity reaction etc. may be observed.
Precaution should be taken in case of impaired renal, hepatic, cardiovascular, cerebrovascular and respiratory failure, prostatic hypertrophy, paralytic ileus, diabetes mellitus, Parkinson's disease and in pregnancy.
Pregnancy: There are no adequate and well-controlled studies in pregnant women.
Lactation: Olanzapine is excreted in breast milk. Patients should be advised not to breast-feed an infant if they are taking Olanzapine.
Olanzapine may antagonize the effects of levodopa and dopamine agonists. Drugs that induce CYP1A2 or glucoronyl transferase enzymes e.g, Omeprazole and Rifampicin, may increase Olanzapine clearance. Inhibitors of CYP1A2 may potentially inhibit Olanzapine elimination. Carbamazepine may increase the clearance of Olanzapine. Concomitant administration of activated charcoal reduces the oral bioavailability of Olanzapine by 50-60%. Caution should be
taken when Olanzapine is administered with centrally acting drugs and alcohol.
Do not store above 30°C. Keep away from light and out of the reach of children.
Olanap 5: Each box contains 5 blister strips of 10 Tablets.
Olanap 5 ODT: Each box contains 3 blister strips of 10 Tablets.
Olanap 10: Each box contains 5 blister strips of 10 Tablets.
Olanap 10 ODT: Each box contains 3 blister strips of 10 Tablets.